share_log

American International Holdings Corp. Launches EPIQ Scripts Online Mail-Order Pharmacy

American International Holdings Corp. Launches EPIQ Scripts Online Mail-Order Pharmacy

美國國際控股公司推出EPIQ Scripts在線郵購藥房
GlobeNewswire ·  2022/02/15 09:06

Adds to AMIH's Portfolio of Complementary Technology Driven, Consumer Focused Healthcare Companies

AdDS至 AMIH‘s 投資組合互補型T工藝學D裂開,以消費者為中心的H醫療保健C公司

Plano, Texas, Feb. 15, 2022 (GLOBE NEWSWIRE) -- American International Holdings Corp. (OTCQB: AMIH), ("AMIH" or the "Company") a diversified holding company that develops, acquires and operates technology-based health and wellness companies, is pleased to announce the launch of EPIQ Scripts, LLC ("EPIQ Scripts"), an online mail-order pharmacy with a specific target to service customers and patients through the growing number of telemedicine companies entering into the market. EPIQ Scripts will initially focus its efforts on obtaining licenses and accreditations in key states with plans to ultimately secure licenses and accreditations in all 50 states across the U.S.

得克薩斯州普萊諾,2022年2月15日(環球通訊社)美國國際控股公司(場外交易市場代碼:AMIH)(以下簡稱“AMIH”或“公司”)是一家多元化控股公司,致力於開發、收購和運營以技術為基礎的健康和保健公司。該公司很高興地宣佈推出EPIQ Scripts,LLC(“EPIQ Scripts”),這是一家在線郵購藥房,其目標是通過越來越多的遠程醫療公司進入市場為客户和患者提供服務。Epiq Scripts最初將專注於在關鍵州獲得許可證和認證,並計劃最終在美國所有50個州獲得許可證和認證。

According to a July 2021 report by All The Research, the Global Online Pharmacy market was valued at $68.2 billion in 2020, and it is expected to reach $202.3 billion by 2027, a compounded annual growth rate (CAGR) of 16.8%. All The Research expects the growth of the online pharmacy market to be attributed to a rise in the number of internet consumers, increased access to online services, increased government support with favorable polices, and the growing execution of e-prescriptions in healthcare facilities.

根據all the Research在2021年7月發佈的一份報告,2020年全球在線藥房市場的價值為682億美元,預計到2027年將達到2023億美元,複合年增長率(CAGR)為16.8%。All The Research預計,在線藥房市場的增長將歸因於互聯網消費者數量的增加,在線服務的增加,優惠政策的政府支持增加,以及醫療機構電子處方的執行日益增多。

In addition to servicing the anticipated demand from the Company's wholly-owned subsidiary, EPIQ MD and its members, EPIQ Scripts plans to market its services to the growing number of telemedicine companies entering the market since early 2020. According to a study by McKinsey & Company, in April 2020, overall telehealth utilization for office visits and outpatient care was 78 times higher than in February 2020. Furthermore, a March 2020 Sykes survey found that by March 2021, more than 61% of Americans had made a telehealth/telemedicine appointment, a massive increase from just 19.5% a year prior.

除了滿足公司全資子公司EPIQ MD及其成員的預期需求外,EPIQ Scripts還計劃從2020年初開始向越來越多進入市場的遠程醫療公司推銷其服務。根據麥肯錫公司(McKinsey&Company)的一項研究,2020年4月,辦公室就診和門診的遠程醫療總體利用率是2020年2月的78倍。此外,賽克斯2020年3月的一項調查發現,到2021年3月,超過61%的美國人預約了遠程醫療/遠程醫療,而一年前只有19.5%。

"With the recent exponential rise in demand for telemedicine, there has been an increase in telehealth and telemedicine platforms," commented Jacob Cohen, President and CEO of American International Holdings Corp., who continued, "This has created a new unmet demand for pharmacies with the capabilities to handle the prescription volume generated by these platforms. We believe that EPIQ Scripts, which is planned to have advanced API capabilities and infrastructure, and supported with nationwide licenses and accreditations, will be able to position itself to capitalize on the current market opportunity and fill this void."

美國國際控股公司(American International Holdings Corp.)總裁兼首席執行官雅各布·科恩(Jacob Cohen)評論説:“隨着最近對遠程醫療的需求呈指數級增長,遠程醫療和遠程醫療平臺的數量也在增加。這創造了對有能力處理這些平臺產生的處方量的藥店的新的未得到滿足的需求。我們相信,EPIQ Scripts計劃擁有先進的API功能和基礎設施,並獲得全國範圍內的許可證和認證支持,它將能夠定位自己,利用當前的市場機遇和認證,並利用這些平臺產生的處方量。我們相信,EPIQ Scripts計劃擁有先進的API功能和基礎設施,並獲得全國範圍內的許可證和認證支持,它將能夠定位自己,利用當前的市場機遇和認證

EPIQ Scripts will be led by pharmacy and healthcare industry veterans, Sultan Haroon and Maja Matthews, who collectively have over 40 years of experience in healthcare, pharmacy ownership, operations, and management.

Epiq Scripts將由製藥和醫療行業資深人士Sultan Haroon和Maja Matthews領導,他們在醫療保健、藥房所有權、運營和管理方面總共擁有40多年的經驗。

"The potential value creation opportunity in online pharmacy solutions has been demonstrated by TruePill, the online pharmacy that provides fulfillment services to popular telemedicine companies Hims and Hers and GoodRx, and which was recently valued at $1.6 billion," commented Sultan Haroon, Manager of Epiq Scripts, who continued, "Our goal is to eventually position EPIQ Scripts to compete with TruePill and other online digital pharmacies as we seek to rapidly rollout our solutions in the sizeable telemedicine markets."

Epiq Scripts的經理蘇爾坦·哈龍(Sultan Haroon)説:“在線藥房TruePill已經證明瞭在線藥房解決方案的潛在價值創造機會。TruePill為廣受歡迎的遠程醫療公司Hims Hers和GoodRx提供履約服務,最近估值為16億美元。我們的目標是最終定位EPIQ Scripts,與TruePill和其他在線數字藥店競爭,因為我們尋求在規模龐大的遠程醫療市場迅速推出我們的解決方案

Sultan Haroon
Mr. Sultan Haroon started his successful pharmacy career with American Specialty Pharmacy. Taking his knowledge, experience, and research, Sultan launched a Pharmacy Consulting Company which connected doctors to ancillary services such as pharmacies, labs, and durable medical equipment companies. Mr. Haroon later went on to establish Whole Health Kinetix (WHK) which specialized in customizing supplements and healthcare according to a patient's blood work and DNA. After its successful launch, WHK was acquired by a group of physicians in the Dallas/Ft Worth metroplex. Sultan then went on to manage, own and operate five Texas Class-A Pharmacies and was also a co-owner of a Class-G Pharmacy. Mr. Haroon grew the pharmacies to several millions of dollars in revenue until they were ultimately purchased by a large east-coast based Venture Capital firm.

蘇丹哈龍
Sultan Haroon先生在美國專業藥房開始了他成功的藥學生涯。蘇爾坦利用他的知識、經驗和研究,創辦了一家藥房諮詢公司,將醫生與藥房、實驗室和耐用醫療設備公司等輔助服務聯繫起來。哈龍先生後來創建了Whole Health Kinetix(WHK),專門根據患者的血常規和DNA定製補充劑和醫療保健。在成功推出後,WHK被達拉斯/沃斯堡大都會的一羣醫生收購。蘇爾坦隨後管理、擁有和運營了五家德克薩斯州A類藥店,也是一家G類藥店的共同所有者。哈龍將藥店的收入提高到了數百萬美元,直到它們最終被東海岸的一家大型風險投資公司收購。

Maja Matthews

馬婭·馬修斯(Maja Matthews)

Drawing on her 27 years of experience in health care, Ms. Matthews provides in-depth knowledge in many facets of the Pharmacy/Health Care Industry. Maja has hands-on experience in management and development of policies & procedures, along with years of experience in credentialing new pharmacies. This includes State Board, NPI, NCPDP, DEA, URAC, all PBM Contracts, State/Federal Compliance, and out of state licensing. Ms. Matthews managed and operated five Texas Class-A Pharmacies and was also Co-Owner of a Class-G Pharmacy. Prior to her venturing out on her own, Maja was District Trainer and Sr. Pharmacy Technician with CVS Pharmacy. She was also Director of Operations and Sr. Technician at American Specialty Pharmacy (ASP) where she managed and trained hundreds of technicians in the processing of prescriptions, auditing, and workers compensation. Maja has been a State Certified Pharmacy Technician since 1996.

憑藉她27年的醫療保健經驗,Matthews女士在製藥/醫療保健行業的許多方面提供了深入的知識。瑪雅在政策和程序的管理和制定方面擁有實踐經驗,並在新藥店認證方面擁有多年經驗。這包括州委員會、NPI、NCPDP、DEA、URAC、所有PBM合同、州/聯邦合規性和州外許可。馬修斯女士管理和經營着五家德克薩斯州A類藥店,也是一家G類藥店的共同所有者。在獨立創業之前,瑪雅是CVS藥房的地區培訓師和高級藥房技術員。她也是董事運營和美國專業藥房的高級技師,在那裏她管理和培訓了數以百計的技術人員,涉及處方處理、審計和工人薪酬。瑪雅自1996年以來一直是一名國家認證藥房技術員。

About American International Holdings Corp.
American International Holdings Corp. (OTCQB: AMIH) is an investor, developer and asset manager of diversified, synergistic health and wellness businesses. Today, the AMIH portfolio encompasses telemedicine and other virtual health platforms, affordable subscriber-based primary care and concierge medicine plans, preventative care solutions and wellness related assets such as mental & behavioral health services, as well as its own proprietary life coaching platform. AMIH markets its various services through direct-to-consumer and business-to-business distribution channels. AMIH's focus is on bringing to market technologies and solutions that advance the quality of life for the global community.

美國國際控股公司簡介
美國國際控股公司(場外交易市場代碼:AMIH)是多元化協同健康業務的投資者、開發商和資產管理公司。今天,AMIH的產品組合包括遠程醫療和其他虛擬健康平臺、負擔得起的基於訂户的初級保健和禮賓醫療計劃、預防性保健解決方案和與健康相關的資產(如心理和行為健康服務),以及自己的專有生活指導平臺。AMIH通過直接對消費者和企業對企業分銷渠道營銷其各種服務。AMIH的重點是將提高全球社會生活質量的技術和解決方案推向市場。

Forward-Looking Statements
This press release may contain forward-looking statements, including information about management's view of the Company's future expectations, plans and prospects, within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management's current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified by the use of words such as "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "would," "could," "will" and other words of similar meaning in connection with a discussion of future operating or financial performance. Examples of forward-looking statements include, among others, statements relating to future sales, operations, expansion, earnings, cash flows, results of operations, uses of cash and other measures of financial performance. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the Company's actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others such as, but not limited to the proposed operations of EPIQ Scripts, the ability of EPIQ Scripts' to obtain required licenses and accreditations, the timing of such licenses and accreditations, and limitations on its operations if such licenses and accreditations are not in place, and future projected revenues, customers, and results of operations of EPIQ Scripts; economic conditions, changes in the laws or regulations, demand for products and services of the Company; our limited operating history; our need for additional funding to support our operations, repay debt and expand our operations; the effects of COVID-19 on our operations and prospects, and the future effects of COVID-19 on us and our operations; impairments we may be required to assess in connection with our assets and goodwill; risks associated with our prior launch of a telehealth platform, including liability in connection therewith, funding needed to support such operations and other risks associated with the operations of the telehealth platform; disruptions to our operations or liabilities associated with future acquisitions; our ability to continue as a going concern; our dependence on our sole officer and director, Jacob D. Cohen, and related party transactions affecting the Company; Mr. Cohen's voting control over the Company; competition we face; our ability to maintain our varied operations, and service our indebtedness; material weaknesses in our controls and procedures; our ability to obtain and maintain adequate insurance; legal challenges and litigation; liability associated with our contracting operations; the terms of Mr. Cohen's employment agreement; dilution caused by the conversion of outstanding notes, exercise of outstanding warrants, and future fund-raising activities; price of, volatility in, and lack of robust trading market for, our common stock; and other factors that could cause actual results to differ materially from those projected or represented in the forward-looking statements. These risk factors and others are included from time to time in filings made by the Company with the Securities and Exchange Commission, including, but not limited to, in the "Risk Factors" sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which it has filed, and files from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

前瞻性陳述
本新聞稿可能包含前瞻性陳述,包括有關管理層對公司未來預期、計劃和前景的看法的信息,符合聯邦證券法的含義,包括1995年的“私人證券訴訟改革法案”。前瞻性陳述也可能包含在公司發佈的其他公開文件中,以及我們的官員和代表不時發表的口頭聲明中。這些前瞻性陳述旨在根據目前被認為有效的假設,提供管理層對我們未來經營和財務業績的當前預期或計劃。它們可以通過使用諸如“預期”、“打算”、“計劃”、“目標”、“尋求”、“相信”、“項目”、“估計”、“預期”、“戰略”、“未來”、“可能”、“應該”、“將會”、“可能”、“將”等與討論未來經營或財務業績相關的類似含義的詞語來識別。前瞻性陳述的例子包括與未來銷售、運營、擴張、收益、現金流、經營結果、現金使用以及其他財務業績衡量標準有關的陳述。由於前瞻性陳述與未來有關,它們會受到固有風險、不確定因素和其他因素的影響,這些風險、不確定因素和其他因素可能會導致公司的實際結果和財務狀況與前瞻性陳述中明示或暗示的大不相同。這些風險、不確定性和其他因素包括但不限於EPIQ Scripts的擬議運營、EPIQ Scripts獲得所需許可證和認證的能力、此類許可證和認證的時間安排、在此類許可證和認證未到位的情況下對其運營的限制,以及未來預計的收入、客户, 這些因素包括:公司業績和經營業績;經濟狀況、法律法規的變化、對公司產品和服務的需求;公司有限的經營歷史;需要額外資金來支持我們的經營、償還債務和擴大經營;新冠肺炎對我們經營和前景的影響,以及新冠肺炎對我們和我們經營的未來影響;我們可能需要評估與我們的資產和商譽相關的減損;與我們以前推出遠程醫療平臺相關的風險,包括與之相關的責任、支持此類業務和其他所需資金。我們的經營中斷或與未來收購相關的負債;我們繼續經營下去的能力;我們對獨家高管和董事的依賴,以及影響公司的關聯方交易;科恩先生對公司的投票權控制;我們面臨的競爭;我們維持我們多樣化業務和償還債務的能力;我們在控制和程序上的重大弱點;我們獲得和維持足夠保險的能力;法律挑戰和訴訟;與我們承包業務相關的責任;科恩先生的僱傭協議的條款;這些因素包括:未償還票據轉換、未償還認股權證的行使和未來籌資活動造成的攤薄;我們普通股的價格、波動性和缺乏強勁的交易市場;以及其他可能導致實際結果與前瞻性表述中預測或表述的結果大不相同的因素。這些風險因素和其他因素包括在公司不時提交給證券交易委員會的文件中,包括但不限於, 在其Form 10-K和Form 10-Q以及Form 8-K中的“風險因素”部分,該公司已向美國證券交易委員會(U.S.Securities and Exchange Commission)提交了文件,並不時地向美國證券交易委員會(U.S.Securities and Exchange Commission)提交文件。這些報告可在www.sec.gov上查閲。本新聞稿中包含的前瞻性陳述僅在本新聞稿發佈之日作出。公司不能保證未來的結果、活動水平、業績或成就。因此,您不應過度依賴這些前瞻性陳述。我們沒有義務公開更新這些前瞻性表述中的任何一項,以反映實際結果、新信息或未來事件、假設的變化或其他影響前瞻性表述的因素的變化,除非適用法律要求。如果我們更新一個或多個前瞻性陳述,不應推斷我們將對這些或其他前瞻性陳述進行額外更新。

Investor Relations Contact
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498

投資者關係聯繫人
首席執行官戴夫·金特里(Dave Gentry)
紅籌公司(RedChip Companies Inc.)
407-491-4498

AMIH@redchip.com
Frank Benedetto
(619) 915-9422

郵箱:amIH@redchip.com
弗蘭克·貝尼代託
(619) 915-9422


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論